Pediatric Status Asthmaticus Follow-up

  • Author: Adam J Schwarz, MD; Chief Editor: Michael R Bye, MD   more...
 
Updated: Oct 26, 2011
 

Further Inpatient Care

  • Indications for ICU admission
    • Altered sensorium
    • Use of continuous inhaled beta-agonist therapy
    • Exhaustion
    • Markedly decreased air entry
    • Rising PCO2 despite treatment
    • Presence of high-risk factors
    • Failure to improve despite adequate therapy
  • Indications for intubation and mechanical ventilation
    • Apnea or respiratory arrest
    • Diminishing level of consciousness
    • Impending respiratory failure marked by significantly rising PCO2 with fatigue, decreased air movement, and altered level of consciousness
    • Significant hypoxemia that is poorly responsive or unresponsive to supplemental oxygen therapy alone
  • Considerations in mechanical ventilation
    • The decision to intubate a patient with asthma is taken with extreme caution. Positive pressure ventilation in a patient with asthma is complicated by severe airway obstruction and air trapping, which results in hyperinflated lungs that may resist further inflation and places the patient at high risk of barotrauma. Therefore, mechanical ventilation should be undertaken only in the face of continued deterioration despite maximal bronchodilatory therapy.
      • Asthma is a disease of airway obstruction (ie, increased airway resistance), resulting in prolongation of the time constant (the time needed for lung units to fill and empty). Slow ventilator rates are usually needed.
      • In the face of high peak airway pressures, the principle of mechanical ventilation of status asthmaticus is controlled hypoventilation, tolerating higher levels of PCO2 in order to minimize tidal volume and peak inspiratory pressures. Permissive hypercapnia can be tolerated as long as the patient remains adequately oxygenated. A longer I:E ratio, often greater than 1:3-4, helps allow time for optimal exhalation, facilitating ventilation and avoiding excessive further air-trapping (auto-PEEP).
    • The use of positive end-expiratory pressure (PEEP) is controversial. A patient with status asthmaticus in respiratory failure on mechanical ventilation usually has a significant amount of air trapping that results in intrinsic PEEP, which may be worsened by maintaining PEEP during exhalation. However, some patients may benefit by the addition of PEEP, perhaps by maintaining airway patency during exhalation. Thus, in a patient who remains refractory to the initial ventilatory settings with no or very low PEEP, cautiously increasing the PEEP may prove beneficial.
    • Traditionally, slow controlled ventilation with heavy sedation, often with muscle relaxation, is used to ventilate patients with status asthmaticus. Caution is warranted, however, as use of muscle relaxants together with high-dose steroids has been associated with the development of prolonged paralysis.
    • Alternatively, some practitioners report ventilating children with status asthmaticus with pressure support alone. This strategy may allow the patient to set his or her own respiratory rate as determined by the physiologic time constant, while assisting ventilation and relieving the fatigue due to significantly increased work of breathing.
    • Noninvasive positive pressure ventilation (NPPV), such as continuous positive airway pressure (CPAP) or bimodal positive airway pressure (BiPAP) delivered through a face mask, has been used for support of status asthmaticus. NPPV has been shown to "splint" the airways, allowing for better exhalation and emptying.
    • Patients require supportive measures and monitoring during mechanical ventilation.
      • Patients may be uncomfortable and air hungry while ventilated with low respiratory rates, prolonged exhalation times, and hypercapnia due to a strategy of controlled hypoventilation.
      • Ideally, monitor flow-volume loops to ascertain if adequate time is provided for exhalation to avoid breath stacking, which occurs if the next breath is delivered before exhalation is completed. Monitoring exhaled tidal volume and auto–positive end-expiratory pressure (auto-PEEP) is also important.
      • Fluids and electrolytes should be monitored. Before arrival in the hospital, children with status asthmaticus have often had diminished oral intake and may have been vomiting because of respiratory difficulty or adverse effects from their medications. This leads to decreased intravascular volume status that may be potentiated by the effects of positive pressure ventilation.
      • In addition, cardiac output may be decreased because of decreased preload that results from air trapping and auto-PEEP. This decreased cardiac output and intravascular volume may be accompanied by metabolic acidosis. Intravascular fluid expansion is needed to treat hypoperfusion, hypotension, or metabolic acidosis. In addition, diastolic hypotension may occasionally result from high doses of beta-agonists. A vasoconstrictor (ie, norepinephrine, phenylephrine) may be considered if significant diastolic hypotension in the face of adequate intravascular volume persists. Monitor serum electrolyte levels, as medications used to treat asthma can result in significant kaliuresis.
  • Indwelling arterial catheters: Placement of indwelling arterial catheters provides continuous blood pressure monitoring, as well as arterial blood gas sampling, in mechanically ventilated patients. Blood gases should be monitored to assess response to mechanical ventilation support.
Next

Further Outpatient Care

  • Outpatient follow-up and continued care of a patient who is hospitalized in the pediatric ICU because of severe status asthmaticus is important in optimizing long-term outcome and quality of life and minimizing recurrent episodes of severe asthma exacerbation.
  • Follow-up is best provided by a specialist in the treatment of asthma.
  • Among the important considerations are home medications, such as anti-inflammatory agents. Corticosteroids are now considered the mainstays of asthma maintenance therapy. Studies indicate that the underuse of anti-inflammatory agents is related to more severe asthma. This is thought to be due to airway remodeling and the persistence of inflammatory changes.
  • Bronchodilators are recommended for acute exacerbations.
  • Environmental management is also necessary in those children with environmental allergies.
Previous
Next

Inpatient & Outpatient Medications

  • Medications include bronchodilators for inhalation such as albuterol, inhaled steroids, oral agents such as leukotriene antagonists, and/or theophylline.
  • Corticosteroid therapy, if indicated, should include written instructions on corticosteroid use.
Previous
Next

Transfer

A child admitted to the ICU with severe status asthmaticus may be considered for transfer to an inpatient ward once the patient meets the following criteria:

  • The child has been successfully extubated.
  • The child has been weaned off continuous intravenous beta-agonists (ie, terbutaline, aminophylline, if used) and is stable on intermittent beta-agonist aerosol therapy.
  • The child can tolerate cessation of continuous albuterol and is converted to intermittent albuterol nebulization at a frequency that can be delivered on the general pediatric floor.
  • The child has a stable hemodynamic status.
Previous
Next

Deterrence/Prevention

  • The goal of chronic asthma therapy is the prevention of admission. This article, however, addresses severe acute exacerbation of asthma (status asthmaticus).
Previous
Next

Complications

Complications may include the following:

  • Cardiac arrest
  • Respiratory failure or arrest
  • Hypoxemia with hypoxic ischemic CNS injury
  • Pneumothorax or pneumomediastinum
  • Toxicity from medications
Previous
Next

Patient Education

Previous
 
Contributor Information and Disclosures
Author

Adam J Schwarz, MD  Consulting Staff, Critical Care Division, Pediatric Subspecialty Faculty, Children's Hospital of Orange County

Adam J Schwarz, MD is a member of the following medical societies: American Academy of Pediatrics and Phi Beta Kappa

Disclosure: Nothing to disclose.

Specialty Editor Board

G Patricia Cantwell, MD, FCCM  Professor of Clinical Pediatrics, Chief, Division of Pediatric Critical Care Medicine, University of Miami, Leonard M Miller School of Medicine; Medical Director, Palliative Care Team, Director, Pediatric Critical Care Transport, Holtz Children's Hospital, Jackson Memorial Medical Center; Medical Manager, FEMA, Urban Search and Rescue, South Florida, Task Force 2; Pediatric Medical Director, Tilli Kids – Pediatric Initiative, Division of Hospice Care Southeast Florida, Inc

G Patricia Cantwell, MD, FCCM is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Heart Association, American Trauma Society, National Association of EMS Physicians, Society of Critical Care Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Barry J Evans, MD  Assistant Professor of Pediatrics, Temple University Medical School; Director of Pediatric Critical Care and Pulmonology, Associate Chair for Pediatric Education, Temple University Children's Medical Center

Barry J Evans, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Mary E Cataletto, MD  Director of Children's Sleep Services, Winthrop Sleep Disorders Center, Mineola, NY; Professor of Clinical Pediatrics, State University of New York at Stony Brook, Stony Brook, NY

Mary E Cataletto, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Chest Physicians

Disclosure: Shering Plough Pharmaceuticals Honoraria Consulting

Chief Editor

Michael R Bye, MD  Professor of Clinical Pediatrics, Division of Pulmonary Medicine, Columbia University College of Physicians and Surgeons; Attending Physician, Pediatric Pulmonary Medicine, Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center

Michael R Bye, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

References
  1. Gorelick M, Scribano PV, Stevens MW, Schultz T, Shults J. Predicting need for hospitalization in acute pediatric asthma. Pediatr Emerg Care. Nov 2008;24(11):735-44. [Medline].

  2. National Asthma Education and Prevention Program (NAEPP) Expert Panel. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. National Heart, Lung, and Blood Institute; August 28, 2007. [Full Text].

  3. [Best Evidence] Andrews T, McGintee E, Mittal MK, et al. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr. Aug 2009;155(2):205-10.e1. [Medline].

  4. [Best Evidence] Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. Mar 2009;123(3):e519-25. [Medline].

  5. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severeacute asthma. Arch Pediatr Adolesc Med. Oct 2000;154(10):979-83. [Medline].

  6. Stephanopoulos DE, Monge R, Schell KH, et al. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med. Oct 1998;26(10):1744-8. [Medline].

  7. Chiang VW, Burns JP, Rifai N, Lipshultz SE, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment. J Pediatr. Jul 2000;137(1):73-7. [Medline].

  8. Kalyanaraman M, Bhalala U, Leoncio M. Serial cardiac troponin concentrations as marker of cardiac toxicity in children with status asthmaticus treated with intravenous terbutaline. Pediatr Emerg Care. Oct 2011;27(10):933-6. [Medline].

  9. Ream RS, Loftis LL, Albers GM, et al. Efficacy of IV theophylline in children with severe status asthmaticus. Chest. May 2001;119(5):1480-8. [Medline]. [Full Text].

  10. Wheeler DS, Jacobs BR, Kenreigh CA, et al. Theophylline versus terbutaline in treating critically ill children with statusasthmaticus: a prospective, randomized, controlled trial. Pediatr Crit Care Med. Mar 2005;6(2):142-7. [Medline].

  11. [Best Evidence] Kim IK, Phrampus E, Venkataraman S, Pitetti R, Saville A, Corcoran T. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics. Nov 2005;116(5):1127-33. [Medline].

  12. Kudukis TM, Manthous CA, Schmidt GA, Hall JB, Wylam ME. Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children. J Pediatr. Feb 1997;130(2):217-24. [Medline].

  13. Anderson M, Svartengren M, Bylin G, Philipson K, Camner P. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis. Mar 1993;147(3):524-8. [Medline].

  14. Hebbar KB, Petrillo-Albarano T, Coto-Puckett W, et al. Experience with use of extracorporeal life support for severe refractory status asthmaticus in children. Crit Care. Mar 2 2009;13(2):R29. [Medline].

  15. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest. Oct 1999;104(8):1001-6. [Medline]. [Full Text].

  16. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol. Oct 1999;104(4 Pt 1):S132-7. [Medline].

  17. Asthma. In: Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 2nd ed. St. Louis, MO: Mosby; 1998:473-5.

  18. Scarfone RJ, Loiselle JM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of childrenwith asthma. Ann Emerg Med. Dec 2000;36(6):572-8. [Medline].

  19. Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dosealbuterol therapy in severe childhood asthma. J Pediatr. Apr 1995;126(4):639-45. [Medline].

  20. Schwarz AJ, Lubinsky PS. Acute severe asthma. In: Levin DL, Morriss FC, eds. Essentials of Pediatric Intensive Care. Vol 1. 2nd ed. 1997:143-56.

  21. Werner HA. Status asthmaticus in children: a review. Chest. Jun 2001;119(6):1913-29. [Medline]. [Full Text].

  22. Yung M, South M. Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child. Nov 1998;79(5):405-10. [Medline]. [Full Text].

  23. Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics. Apr 1999;103(4 Pt 1):748-52. [Medline]. [Full Text].

Previous
Next
 
Figure depicting antigen presentation by the dendritic cell with the lymphocyte and cytokine response leading to airway inflammation and asthma symptoms.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.